Nektar Therapeutics (NKTR) Highlights Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer
November 7, 2019 10:24 AM ESTOppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a Perform rating.
The analyst commented, "Nektar reported 3Q19 financial results, revised 2019 guidance, and provided pipeline updates including multiple catalysts. While NKTR has several promising... More
Nektar Therapeutics (NKTR) PT Lowered to $40 at Cowen
November 7, 2019 8:26 AM ESTCowen lowered its price target on Nektar Therapeutics (NASDAQ: NKTR) to $40.00 (from $43.00) while maintaining a Outperform rating.... More
Nektar Therapeutics (NKTR) PT Lowered to $35 at Piper Jaffray
November 7, 2019 6:57 AM ESTPiper Jaffray analyst Tyler Van Buren lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $35.00 (from $50.00) while maintaining a Overweight rating.... More
